Zusammenfassung
Indikationen, Wirkungsweise, Nebenwirkungen und Risiken, Kontraindikationen und Interaktionen werden für die Medikamente zur Behandlung der ADHS im allgemeinen Teil und dann für jedes Arzneimittel spezifisch im Präparateteil beschrieben.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Literatur
Ashock AH, Mizuno Y, Volkow ND et al (2017) Association of stimulant use with dopaminergic alterations in users of cocaine, amphetamine, or methamphetamine. A systematic review and meta-analysis. JAMA Psychiatry 74(5): 511–519
Asherson P (2017) Drug treatment for ADHD reduce risk of substance use disorder. Am J Psychiatry 174(9): 827–828
Banaschewski T, Becker K, Döpfner M et al (2017) Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung. Eine aktuelle Bestandsaufnahme. Dt Ärztebl 114(9): 149–159
Banaschewski T, Hohmann S, Millenet S et al (2018) Langfassung der interdiziplinären evidenz- und konsensbasierten (S3) Leitlinie „Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) im Kindes-, Jugend- und Erwachsenenalter“. AWMF-Registernummer 028-045
Buoli M, Serati M, Cahn W (2016) Alternative pharmacological strategies for adult ADHD treatment: a systematic review. Expert Rev Neurother 16(2): 131–144
Chang Z, Quinn PD, Hur K et al (2017) Association between medication use for attention-deficit/hyperactivity disorder and risk of motor vehicle crashes. JAMA Psychiatry 74(6): 597–603
Cortese S, Moreira-Maia CR, St Fleur D et al (2016) Association between ADHD and obesity: a systematic review and meta-analysis. Am J Psychiatry 173(1): 34–43
Dalsgaard S, Kvist AP, Leckman JF et al (2014) Cardiovascular safety of stimulants in children with attention-deficit/hyperactivity disorder: a nationwide prospective cohort study. J Child Adolesc Psychopharmacol 24(6): 302–310
Franke AG, Northoff R, Hildt E (2015) The case of pharmacological neuroenhancement: medical, judicial and ethical aspects from a German perspective. Pharmacopsychiatry 48(7): 256–264
Hart H, Radua J, Nakao T et al (2013) Meta-analysis of functional magnetic resonance imaging studies of inhibition and attention in attention-deficit/hyperactivity disorder: exploring task-specific, stimulant medication, and age effects. JAMA Psychiatry 70(2): 185–198
Hennissen L, Bakker MJ, Banaschewski T (2017) Cardiovascular effects of stimulant and non-stimulant medication for children and adolescents with ADHD: a systematic review and meta-analysis of trials of methylphenidate, amphetamines and atomoxetine. CNS Drugs 31(3): 199–215
Ji N, Findling RL (2015) An update of pharmacotherapy for autism spectrum disorder in children and adolescents. Curr Opin Psychiatry 28(2): 91–101
Kratochvil C (2012) ADHD pharmacotherapy: rates of stimulant use and cardiovascular risk. Am J Psychiatry 169(2): 112–114
Lu Y, Sjölander A, Cederlöf M et al (2017) Association between medication use and performance on higher education entrance tests in individuals with attention-deficit/hyperactivity disorder. JAMA Psychiatry 74(8): 815–822
Linderkamp F, Lauth G (2011) Zur Wirksamkeit pharmakologischer und psychotherapeutischer Therapien bei Aufmerksamkeitsdefizit-/Hyperaktivitätsstörungen (ADHS) im Erwachsenenalter: Eine empirische Metanalyse. Verhaltenstherapie 21: 229–238
Moffitt TE, Houts R, Asherson P et al (2015) Is adult ADHD a childhood neurodevelopmental disorder? Evidence from a four-decade longitudinal cohort study. Am J Psychiatry 172(10): 967–977
Ooi YP, Weng SJ, Kossowsky J et al (2017) Oxytocin and autism spectrum disorder: a systematic review and meta-analysis of randomized controlled trials. Pharmacopsychiatry 50(1): 5–13
Roll SC, Hahn M (2015) Neue Studien zu ADHS im Erwachsenenalter. DNP 16(2): 26–28
Ustun B, Adler LA, Rudin C et al (2017) The World Health Organization Adult Attention-deficit/Hyperactivtiy Disorder Self-Report Screening Scale for DSM-5. JAMA Psychiatry 74(5) 520–526
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer-Verlag GmbH Deutschland
About this chapter
Cite this chapter
Heiser, P., Benkert, O. (2019). Medikamente zur Behandlung von ADHS und anderen Entwicklungsstörungen. In: Benkert, O., Hippius, H. (eds) Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-57334-1_10
Download citation
DOI: https://doi.org/10.1007/978-3-662-57334-1_10
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-57333-4
Online ISBN: 978-3-662-57334-1
eBook Packages: Medicine (German Language)